share_log

HC Wainwright & Co. Upgrades Diffusion Pharmaceuticals to Buy, Announces $9.5 Price Target

Benzinga Real-time News ·  Aug 16, 2022 18:30

HC Wainwright & Co. analyst Swayampakula Ramakanth upgrades Diffusion Pharmaceuticals (NASDAQ:DFFN) from Neutral to Buy and announces $9.5 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment